Drug- or toxin-induced pulmonary arterial hypertension Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Jun 2026Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

Mayo Clinic — PHASE1

TrialRECRUITING

Jun 2026Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension

University Hospital, Rouen — NA

TrialNOT YET RECRUITING

May 2026Clinical Trial of 2-HOBA in Pulmonary Arterial Hypertension

Vanderbilt University Medical Center — PHASE2

TrialNOT YET RECRUITING

Apr 2026A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Insmed Incorporated — PHASE3

TrialNOT YET RECRUITING

Mar 2026Long-Term Open-Label Extension Study of Oral Levosimendan

Tenax Therapeutics, Inc. — PHASE3

TrialENROLLING BY INVITATION

Mar 2026LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Tenax Therapeutics, Inc. — PHASE3

TrialRECRUITING

Mar 2026An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)

Inhibikase Therapeutics — PHASE3

TrialNOT YET RECRUITING

Mar 2026PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension

Samsung Medical Center — PHASE1

TrialNOT YET RECRUITING

Jan 2026Phase 2 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Regeneron Pharmaceuticals — PHASE2

TrialNOT YET RECRUITING

Jan 2026Exercise Intervention as an Adjunct to Medical Therapy in Newly Diagnosed Patients With Pulmonary Arterial Hypertension

Golden Jubilee National Hospital — NA

TrialNOT YET RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Drug- or toxin-induced pulmonary arterial hypertension.
Check the disease page for updates →

Clinical Trial Landscape

53 active trials

7Phase 3

3Phase 4

10Phase 2

3Phase 1

9N/A

16Unknown

2PHASE2, PHASE3

2PHASE1, PHASE2

1EARLY_PHASE1

53Total recruiting

Search clinical trials for Drug- or toxin-induced pulmonary arterial hypertension →

Recent News & Research

No recent news articles indexed yet for Drug- or toxin-induced pulmonary arterial hypertension.
Search PubMed for Drug- or toxin-induced pulmonary arterial hypertension →

Browse all Drug- or toxin-induced pulmonary arterial hypertension news →

Specialist Network

Top 6 by expertise

Ekkehard Grünig, MD

Thoraxclinic at the University of Heidelberg

Score 254 trials

Nicholas S Hill, MD

Tufts Medical Center

Score 115 trials

Sudarshan Rajagopal, MD, PhD, M.D

Duke Health System

📍 DURHAM, NC

Score 113 trials

Richard Aranda

Gossamer Bio Inc.

Score 82 trials1 pub

Horst Olschewski, MD

Medical University of Graz

Score 89 trials

Andjela Kusic-Pajic, MD

Actelion

Score 62 trials1 pub

View all Drug- or toxin-induced pulmonary arterial hypertension specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰